{"denoms":[{"counts":[{"groupId":"BG000","value":"110"},{"groupId":"BG001","value":"110"},{"groupId":"BG002","value":"220"}],"units":"Participants"}],"groups":[{"description":"Idelalisib 150 mg tablet administered orally twice daily plus rituximab (8 intravenous doses through Week 20: Day 1: 375 mg/m\\^2, and 500 mg/m\\^2 thereafter)","id":"BG000","title":"Idelalisib + Rituximab"},{"description":"Placebo to match idelalisib administered orally twice daily plus rituximab (8 intravenous doses through Week 20: Day 1: 375 mg/m\\^2, and 500 mg/m\\^2 thereafter)","id":"BG001","title":"Placebo + Rituximab"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"7.7","value":"71"},{"groupId":"BG001","spread":"8.1","value":"70"},{"groupId":"BG002","spread":"7.9","value":"71"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"48"}]}],"title":"< 65 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"89"},{"groupId":"BG001","value":"83"},{"groupId":"BG002","value":"172"}]}],"title":"≥ 65 years"}],"paramType":"NUMBER","title":"Age, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"34"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"76"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"76"},{"groupId":"BG001","value":"68"},{"groupId":"BG002","value":"144"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"5"}]}],"title":"Hispanic or Latino"},{"categories":[{"measurements":[{"groupId":"BG000","value":"101"},{"groupId":"BG001","value":"102"},{"groupId":"BG002","value":"203"}]}],"title":"Not Hispanic or Latino"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"12"}]}],"title":"Not Permitted"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"100"},{"groupId":"BG001","value":"98"},{"groupId":"BG002","value":"198"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"}]}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"}]}],"title":"Other"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"12"}]}],"title":"Not Permitted"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"}]}],"title":"France"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"12"}]}],"title":"Germany"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"7"}]}],"title":"Italy"},{"categories":[{"measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"32"}]}],"title":"United Kingdom"},{"categories":[{"measurements":[{"groupId":"BG000","value":"80"},{"groupId":"BG001","value":"83"},{"groupId":"BG002","value":"163"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}]}],"title":"40"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"7"}]}],"title":"50"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"11"}]}],"title":"60"},{"categories":[{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"33"}]}],"title":"70"},{"categories":[{"measurements":[{"groupId":"BG000","value":"42"},{"groupId":"BG001","value":"46"},{"groupId":"BG002","value":"88"}]}],"title":"80"},{"categories":[{"measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"51"}]}],"title":"90"},{"categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"28"}]}],"title":"100"}],"description":"Classifies patients according to their functional impairment. Scores range from 0-100; the lower the score, the worse the survival for most serious illnesses.","paramType":"NUMBER","title":"Karnofsky Performance Status","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"62.28","value":"108.3"},{"groupId":"BG001","spread":"52.73","value":"106.4"},{"groupId":"BG002","spread":"57.58","value":"107.4"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Time Since Diagnosis","unitOfMeasure":"months"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}],"title":"Rai Stage 0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"37"}]}],"title":"Rai Stage 1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"26"}]}],"title":"Rai Stage 2"},{"categories":[{"measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"40"}]}],"title":"Rai Stage 3"},{"categories":[{"measurements":[{"groupId":"BG000","value":"48"},{"groupId":"BG001","value":"54"},{"groupId":"BG002","value":"102"}]}],"title":"Rai Stage 4"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"14"}]}],"title":"Missing"}],"description":"Rai staging categorizes the disease progression of chronic lymphocytic leukemia (CLL), with classifications of low- (Stage 0), intermediate- (Stage 1 and 2), and high-risk (Stages 3 and 4) categories. Rai Stage 0: high number of lymphocytes in the blood (lymphocytosis) only. Rai Stage 1: lymphocytosis with enlarged lymphoid tissues (lymphadenopathy). Rai Stage 2: lymphocytosis with enlarged liver (hepatomegaly) or spleen (splenomegaly). Rai Stage 3: lymphocytosis with low red blood cell count (anemia). Rai Stage 4: lymphocytosis with low number of blood platelets (thrombocytopenia).","paramType":"NUMBER","title":"Rai Stage at Screening","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"11"}]}],"title":"Binet Stage A"},{"categories":[{"measurements":[{"groupId":"BG000","value":"29"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"61"}]}],"title":"Binet Stage B"},{"categories":[{"measurements":[{"groupId":"BG000","value":"63"},{"groupId":"BG001","value":"60"},{"groupId":"BG002","value":"123"}]}],"title":"Binet Stage C"},{"categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"25"}]}],"title":"Missing"}],"description":"Binet staging classifies CLL according to the number of lymphoid tissues involved, as well as the presence of anemia or thrombocytopenia. Stage A: fewer than three areas of enlarged lymphoid tissue; enlarged lymph nodes of the neck, underarms, and groin, as well as the spleen, are each considered \"one group\" whether unilateral (one-sided) or bilateral (on both sides). Binet Stage B: more than three areas of enlarged lymphoid tissue. Binet Stage C: anemia plus thrombocytopenia.","paramType":"NUMBER","title":"Binet Stage at Screening","unitOfMeasure":"participants"}],"populationDescription":"ITT Analysis Set: randomized participants with treatment group designated according to initial randomization."}